Suggestions
Hillary Lin
Stanford MD & Founder, Healthtech Startups, Longevity
Dr. Hillary Lin is the Co-Founder and CEO of Curio, a healthcare startup that leverages artificial intelligence to enhance patient navigation and address health equity. She is a Stanford-trained physician with a strong background in neuroscience, oncology, and internal medicine. Dr. Lin completed her BS and MD at Stanford University, followed by her residency in internal medicine.124
At Curio, Dr. Lin leads initiatives aimed at simplifying the healthcare experience for patients, particularly in the oncology space. The platform originally focused on psychedelic-assisted therapy but has since evolved to provide comprehensive care solutions that integrate mental health support and personalized navigation through complex healthcare systems. Her work emphasizes the importance of empathetic, technology-driven care to improve patient outcomes and adherence to treatment.135
As a Taiwanese immigrant, Dr. Lin's personal experiences with healthcare disparities have fueled her passion for creating a more accessible and supportive healthcare environment. She is also involved in advising other health tech startups and contributes to various healthcare initiatives aimed at improving patient care and outcomes.124
Highlights
Last week, I was admittedly very hesitant about the staying power (or longevity!) of the longevity medicine wave. It feels like a privileged trend, made for the the wealthy and tough to scale.
But after attending the Longevity Docs inaugural mastermind here in NYC, I can see the throughline now from today's state to a future we all are hoping for.
At its core, longevity medicine is about taking a proactive, personalized approach to extending healthspan and lifespan. As Anant Vinjamoori, MD put it, "Longevity medicine is meeting patients where they are and getting them to where they want to be." It's highly tailored to individual goals and risk tolerance.
However, with this cutting-edge approach comes the need for caution. Longevity interventions often rely on limited evidence compared to guidelines for population health. Physicians must carefully balance the desire to optimize individual outcomes with the risk of overtreatment, as seen in the well-described "VIP syndrome."
Still, I left the mastermind feeling extraordinarily optimistic about the potential of longevity medicine. Many thanks to David Luu, MD for putting together the best conference I've been to in memory! There are too many experts and leaders for me to mention in this post, but I want to also call out and thank the incredible Jessica Shepherd, MD, MBA, FACOG (hands down best moderator in the universe) and James Peyer, PhD for enlightening us all why rapamycin has been so tough to study as a longevity drug.
By breaking down the psychological barriers around human lifespan and healthspan, this field promises to unlock tremendous advances in the years to come. I look forward to being part of the journey. I even went ahead and wrote up a thought piece on the topic: https://lnkd.in/gjKEuNYy
I'm curious for my readers - what do you make of the longevity medicine? A lasting revolution or passing fad?
Oh good, we can finally renew medical licenses online!
But... Internet Explorer?? 😂😅🤦🏻♀️
